<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398398</url>
  </required_header>
  <id_info>
    <org_study_id>AMC0603</org_study_id>
    <secondary_id>EMR 62202-723,OXALI_L_01600</secondary_id>
    <nct_id>NCT00398398</nct_id>
  </id_info>
  <brief_title>Study of XELOX With Cetuximab in Advanced Gastric Cancer</brief_title>
  <official_title>A Prospective Phase II Study of Cetuximab (Erbitux®) in Combination With XELOX [XELoda® (Capecitabine) and OXaliplatin] in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of capecitabine and oxaliplatin as 'backbone' regimen, adding a newer&#xD;
      biologic agent, cetuximab, is a reasonable strategy of further chemotherapy development in&#xD;
      advanced gastric cancer, which is the investigators study rationale.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is presently no chemotherapy regimen considered to be the global standard of care for&#xD;
      patients with AGC, and there is still a need for new agents and/or regimens to improve the&#xD;
      efficacy and safety of chemotherapy in advanced stomach cancers.&#xD;
&#xD;
      The combination of 5-fluorouracil plus cisplatin (FP) has been widely used for the first-line&#xD;
      treatment of advanced gastric cancer in many countries.&#xD;
&#xD;
      Randomized phase III trial investigating capecitabine plus cisplatin(XP) versus FP showed XP&#xD;
      is at least as good as FP with improved patients' preference.&#xD;
&#xD;
      A Phase II study of capecitabine plus oxaliplatin (XELOX) was conducted in our study group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Tumor response was evaluated every two cycles by CT scans and other indicated methods, and the patients with complete or partial response required a confirmatory response evaluation at least 4 weeks later. Patients without confirmatory evaluation were not regarded as responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Profile</measure>
    <time_frame>1 years</time_frame>
    <description>Number of patients who experienced toxicity from study treatment to evaluate the safety and tolerability of XELOX plus Cetuximab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitbine, oxaliplatin, cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitbine, oxaliplatin and cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine, Oxaliplatin, Cetuximab</intervention_name>
    <description>Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.</description>
    <arm_group_label>Capecitbine, oxaliplatin, cetuximab</arm_group_label>
    <other_name>xeloda, oxalitin, Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having given signed written informed consent&#xD;
&#xD;
          -  Patients must have histologically or cytologically documented stomach adenocarcinoma&#xD;
             including adenocarcinoma of the esophagogastric junction.&#xD;
&#xD;
          -  Patients must have unresectable metastatic disease or recurrent disease after curative&#xD;
             surgical resection with uni-dimensionally measurable disease according to RECIST (at&#xD;
             least longest diameter 1 cm on computed tomography scan, or at least 2 cm on chest&#xD;
             x-ray or physical examination&#xD;
&#xD;
          -  Age 18 to 70 years old&#xD;
&#xD;
          -  Estimated life expectancy of more than 3 months&#xD;
&#xD;
          -  ECOG performance status &lt; 2 (See Appendix E)&#xD;
&#xD;
          -  Adequate bone marrow function (WBC&gt;3,000/µL, ANC&gt;1,500/µL, and platelets&gt;100,000/µL,&#xD;
             Hb&gt;8g/dl)&#xD;
&#xD;
          -  Adequate kidney function (creatinine&lt;1.5 mg/dL)&#xD;
&#xD;
          -  Adequate liver function [bilirubin&lt; 2.0 mg/dL, transaminases levels&lt;3 times the Upper&#xD;
             Normal Value (5 times for patients with liver metastasis)]&#xD;
&#xD;
          -  Prothrombin time not less than 50% of Lower Normal Value&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No prior radiation therapy&#xD;
&#xD;
          -  Patients must not have psychological, familial, sociological or geographical&#xD;
             conditions which do not permit medical follow-up and compliance with this study.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum HCG pregnancy test on&#xD;
             admission. Men and women of reproductive potential must have agreed to use an&#xD;
             effective method of contraception while on treatment and for 6 months after study&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past or concurrent history of neoplasm other than gastric adenocarcinoma within the&#xD;
             last five years, except for curatively treated non-melanoma skin cancer or in situ&#xD;
             carcinoma of the cervix uteri.&#xD;
&#xD;
          -  Central nervous system (CNS) metastases.&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to study treatment start&#xD;
&#xD;
          -  Gastric outlet obstruction, intestinal obstruction and obvious peritoneal seeding.&#xD;
&#xD;
          -  Evidence of serious gastrointestinal bleeding.&#xD;
&#xD;
          -  The patient has bony lesions as the sole evaluable disease.&#xD;
&#xD;
          -  Pregnant or lactating women, women of childbearing potential not employing adequate&#xD;
             contraception.&#xD;
&#xD;
          -  Patients with sensory neuropathy (grade&gt; 1 according to NCI CTCAE v. 3.0).&#xD;
&#xD;
          -  Hypersensitivity to any of the study drugs or ingredients.&#xD;
&#xD;
          -  Other serious illness or medical conditions that would not allow study participation&#xD;
             in the best interest of the patient as decided by the investigator.&#xD;
&#xD;
          -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months&#xD;
             prior to study entry.&#xD;
&#xD;
          -  History of significant neurologic or psychiatric disorders including dementia or&#xD;
             seizures.&#xD;
&#xD;
          -  Active uncontrolled infection.&#xD;
&#xD;
          -  Pre-existing clinically significant diarrhea.&#xD;
&#xD;
          -  Unstable diabetes mellitus.&#xD;
&#xD;
          -  Severe hypercalcemia of &gt; 12 mg/dL and uncontrolled with bisphosphonates.&#xD;
&#xD;
          -  Active disseminated intravascular coagulation.&#xD;
&#xD;
          -  Concurrent treatment with corticosteroids (or equivalent) except as use for the&#xD;
             prophylactic medication regimen, treatment of acute hypersensitivity reactions or&#xD;
             nausea, or unless chronic treatment (initiated &gt; 6 months prior to study entry) at low&#xD;
             dose (&lt;20 mg methyl prednisolone or equivalent).&#xD;
&#xD;
          -  Concomitant or administration of any other experimental drug under investigation&#xD;
             within 4 weeks before the study.&#xD;
&#xD;
          -  Concomitant or previous hormonal therapy, or immunotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <results_first_submitted>December 15, 2013</results_first_submitted>
  <results_first_submitted_qc>October 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 1, 2015</results_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>cetuximab</keyword>
  <keyword>capecitabine</keyword>
  <keyword>oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Xelox Plus Cetuximab</title>
          <description>Capecitabine, oxaliplatin and cetuximab&#xD;
cetuximab : initial loading dose of 400 mg/m2, maintenance dose of 250 mg/m2 (every week) Oxaliplatin : 130 mg/m2 (every 3 weeks) capecitabine :1,000 mg/m2 (days 1-14)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Xelox Plus Cetuximab</title>
          <description>Capecitabine, oxaliplatin and cetuximab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" lower_limit="36" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Tumor response was evaluated every two cycles by CT scans and other indicated methods, and the patients with complete or partial response required a confirmatory response evaluation at least 4 weeks later. Patients without confirmatory evaluation were not regarded as responders.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xelox Plus Cetuximab</title>
            <description>Capecitabine, oxaliplatin and cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Tumor response was evaluated every two cycles by CT scans and other indicated methods, and the patients with complete or partial response required a confirmatory response evaluation at least 4 weeks later. Patients without confirmatory evaluation were not regarded as responders.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xelox Plus Cetuximab</title>
            <description>Capecitabine, oxaliplatin and cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.9" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xelox Plus Cetuximab</title>
            <description>Capecitabine, oxaliplatin and cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="6.7" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Profile</title>
        <description>Number of patients who experienced toxicity from study treatment to evaluate the safety and tolerability of XELOX plus Cetuximab</description>
        <time_frame>1 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xelox Plus Cetuximab</title>
            <description>Capecitabine, oxaliplatin and cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Profile</title>
          <description>Number of patients who experienced toxicity from study treatment to evaluate the safety and tolerability of XELOX plus Cetuximab</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year after completion of study treatment. If patients received another treatment, toxicity assessment was not done further.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Xelox Plus Cetuximab</title>
          <description>Capecitabine, oxaliplatin and cetuximab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI_CTCAE_v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood disorder</sub_title>
                <description>Mood fluctuation during treatment. But this was assessed as unlikely to be related to study treatment.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI_CTCAE_v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Aspartate aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Elevated alanine transferase</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Elevated bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Acneiform rash</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yoon-Koo Kang</name_or_title>
      <organization>Asan Medical Center</organization>
      <phone>+82-2-3010-3210</phone>
      <email>ykkang@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

